hy announed on the 6th that it had signed a business agreement with IMMUNOBIOME to develop probiotic-based supplements and medicine (LBP).
With this agreement as an aopportunity, hy will start developing 'pharmabiotics'. Through this, the area of application of probiotics, which was limited to food and supplements, will be expanded to the category of therapeutics. Pharmabiotics are live microorganisms for the treatment of diseases. The related market size reached 160 billion won in 2019 and is expected to grow to 10 trillion won by 2024.